Skip to main content
Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.2400
-0.0100 (-4.00%)
Jun 27, 2025, 3:59 PM EDT

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2016 - 2018
Period Ending
 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2016 - 2018
Innovative Immunotherapies for Cancer
1.93M
Log In
Log In
Log In
Log In
Upgrade
Innovative Immunotherapies for Cancer Growth
14.80%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2016 - 2018
Period Ending
 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2016 - 2018
United States, Germany, United Kingdom and Netherlands
1.93M
Log In
Log In
Log In
Log In
Upgrade
United States, Germany, United Kingdom and Netherlands Growth
14.80%
Log In
Log In
Log In
Log In
Upgrade